

Biomarker and AI-supported FX06 therapy to prevent the progression from mild and moderate to severe stages of COVID-19.


OUR GOALS

Around 14% of COVID-19 patients with mild or moderate symptoms develop to severe and are eventually admitted to intensive care units. The main goal of the COVend project is to reduce the number of COVID-19 patients in hospitals and thus the burden on patients and their families, clinical staff and the healthcare sector. More specifically, firstly we aim to enrich the current portfolio of SARS-CoV-2 / COVID-19 prophylactic and therapeutic agents through the clinical testing of FX06, a promising drug candidate. Secondly, we aim to provide an effective therapy against SARS-CoV-2 by using innovative immune biomarker profiles, methods for evaluating endothelial cells and models driven by artificial intelligence to support decision-making for the clinical treatment of COVID-19. This is to prevent the disease from progressing to severe illness and hospitalization.

HOW DOES IT WORK?

Endothelial cells are the main regulators of vascular homeostasis (dynamic equilibrium) as they interact with both circulating cells and those present in the vessel wall. When endothelial function deteriorates, vascular homeostasis is impaired and leads to increased permeability for blood components and inflammation of the endothelium. FX06 has a protective effect on the endothelium and reduces the inflammatory process driven by COVID-19.

The progression of the disease to severe is thus interrupted by the use of FX06, which leads to a faster recovery of the patient and fewer admissions to intensive care units.



FX06 →

DURATION

01.08.2021 – 31.07.2024

BUDGET

9.9 million Euro

FUNDING PROGRAMME

HORIZON-HLTH-2021-CORONA-01-01

COORDINATOR

Johann Wolfgang Goethe Universität Frankfurt am Main, DE (Hessen) 

PARTNERS

- Fraunhofer Institute for Translational Medicine and Pharmacology, DE 
- Medical Intelligent Data Analytics GmbH, DE
- University Hospital Würzburg, DE
- accelopment Schweiz AG, CH 
- European Society of Anaesthesiology and Intensive Care, BE 
- F4-Pharma GmbH, AT
- Tampere University, FI 
- University College Dublin, IE
- University Medical Center Groningen, NL 
- ASST Fatebenefratelli Sacco – Luigi Sacco Hospital, IT 
- Ospedale S. Maria della Misericordia, University of Perugia, IT
- Hospital of Lithuanian University of Health Sciences Kaunas Clinics, LT 
- Hospital Universitario de Bellvitge, ES 
- Carol Davila University of Medicine and Pharmacy, RO 
- Centro Hospitalar e Universitario de Coimbra E.P.E., PT 
- Assistance Publique Hopitaux de Paris, FR 



Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union. Neither the European Union nor the granting authority can be held responsible for them.